Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

BRD2 inhibitor

DRUG CLASS:

BRD2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

MLL translocation	Acute Myelogenous Leukemia	MLL translocation	Acute Myelogenous Leukemia	OTX015 Resistant: C3 – Early Trials OTX015 Resistant : C3	OTX015 Resistant: C3 – Early Trials OTX015 Resistant : C3
SPI1 deletion	Acute Myelogenous Leukemia	SPI1 deletion	Acute Myelogenous Leukemia	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3
MTHFR underexpression	Acute Myelogenous Leukemia	MTHFR underexpression	Acute Myelogenous Leukemia	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials venetoclax + sunitinib + I-BET151 Sensitive : C3	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials venetoclax + sunitinib + I-BET151 Sensitive : C3
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
MYCL overexpression	Multiple Myeloma	MYCL overexpression	Multiple Myeloma	I-BET151 Sensitive: D – Preclinical I-BET151 Sensitive : D	I-BET151 Sensitive: D – Preclinical I-BET151 Sensitive : D
TERT rearrangement	Neuroblastoma	TERT rearrangement	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
ARID1A mutation	Bladder Cancer	ARID1A mutation	Bladder Cancer	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D